Journal article icon

Journal article

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2)

Abstract:

Background: To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenovirus type 26 vector-based vaccine (Ad26.ZEBOV), expressing Zaire Ebola virus glycoprotein, and a non-replicating, recombinant, modified vaccinia Ankara (MVA) vector-based vaccine, encoding glycoproteins from Zaire Ebola virus, Sudan v...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S1473-3099(20)30476-X

Authors


More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Division:
MSD
Department:
Paediatrics
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Author
More from this funder
Name:
European Commission
Grant:
115861
More from this funder
Name:
Oxford Biomedical Research Centre
Grant:
BZR01462
More from this funder
Name:
National Institute for Health Research
Grant:
NF-SI-0617-10036
Publisher:
Elsevier
Journal:
Lancet Infectious Diseases More from this journal
Volume:
21
Issue:
4
Pages:
493-506
Publication date:
2020-11-17
Acceptance date:
2020-05-06
DOI:
EISSN:
1474-4457
ISSN:
1473-3099
Language:
English
Keywords:
Pubs id:
1137412
Local pid:
pubs:1137412
Deposit date:
2020-10-13

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP